DE3872029D1 - Rektal absorbierbare form von l-dopa. - Google Patents

Rektal absorbierbare form von l-dopa.

Info

Publication number
DE3872029D1
DE3872029D1 DE8888303306T DE3872029T DE3872029D1 DE 3872029 D1 DE3872029 D1 DE 3872029D1 DE 8888303306 T DE8888303306 T DE 8888303306T DE 3872029 T DE3872029 T DE 3872029T DE 3872029 D1 DE3872029 D1 DE 3872029D1
Authority
DE
Germany
Prior art keywords
dopa
rectally
absorbable shape
shape
rectally absorbable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888303306T
Other languages
English (en)
Other versions
DE3872029T2 (de
Inventor
A J Repta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE3872029D1 publication Critical patent/DE3872029D1/de
Publication of DE3872029T2 publication Critical patent/DE3872029T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE8888303306T 1987-04-17 1988-04-13 Rektal absorbierbare form von l-dopa. Expired - Lifetime DE3872029T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/039,406 US4771073A (en) 1985-12-30 1987-04-17 Rectally absorbable form of L-dopa

Publications (2)

Publication Number Publication Date
DE3872029D1 true DE3872029D1 (de) 1992-07-23
DE3872029T2 DE3872029T2 (de) 1992-12-03

Family

ID=21905277

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888303306T Expired - Lifetime DE3872029T2 (de) 1987-04-17 1988-04-13 Rektal absorbierbare form von l-dopa.

Country Status (4)

Country Link
US (1) US4771073A (de)
EP (1) EP0287341B1 (de)
JP (1) JPH01268633A (de)
DE (1) DE3872029T2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
WO2000027385A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd., Et Al. Dispersible compositions containing l-dopa ethyl ester
JP2002529443A (ja) 1998-11-10 2002-09-10 テバ ファーマシューティカル インダストリーズ リミティド Ｌ−ドーパエチルエステルの製造方法
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
EP1808169B8 (de) 1999-12-30 2012-07-04 Proteotech Inc. Polyhydroxylierte aromatische Verbindungen zur Behandlung von Amyloidose und $g(a)-Synuklein-Fibrillen-Erkrankungen
AU2003293423A1 (en) * 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
ATE495739T1 (de) 2003-08-29 2011-02-15 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
ZA200610042B (en) * 2004-06-04 2008-06-25 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
DK1959948T3 (da) * 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
US9173862B2 (en) * 2008-04-18 2015-11-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
EP2349973A2 (de) * 2008-10-20 2011-08-03 XenoPort, Inc. Verfahren zur synthese einer levodopa ester-prodrug
JP2013520521A (ja) 2009-11-09 2013-06-06 ゼノポート，インコーポレーテッド レボドパプロドラッグの医薬組成物及び経口剤形並びに使用方法
DK3075723T3 (en) 2015-03-30 2017-09-11 Berlirem Gmbh High-resolution L-DOPA glycerol esters
AU2016239274A1 (en) * 2015-03-30 2017-11-02 Berlirem Gmbh Water-soluble L-DOPA esters
WO2018059739A1 (en) 2016-09-29 2018-04-05 Berlirem Gmbh L-dopa derivatives for the treatment of neurological diseases
EP3917504A1 (de) 2019-01-31 2021-12-08 Arizona Board of Regents on behalf of the University of Arizona Zusammensetzungen und verfahren zur behandlung oder begrenzung der entwicklung altersbedingter makuladegeneration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3787581A (en) * 1970-03-24 1974-01-22 M Sandler Pharmaceutical compositions and methods of treatment
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
EP0287341A1 (de) 1988-10-19
JPH01268633A (ja) 1989-10-26
DE3872029T2 (de) 1992-12-03
EP0287341B1 (de) 1992-06-17
US4771073A (en) 1988-09-13

Similar Documents

Publication Publication Date Title
DE3872029D1 (de) Rektal absorbierbare form von l-dopa.
DE3879806D1 (de) Polymerisierung von aethylen.
ATE72660T1 (de) Herstellung von zeolith-l.
DK393888A (da) Vaskemiddel
DK381487D0 (da) Mekanisk ledbaand
DE69018071D1 (de) Herstellung von peroxysäuren.
DE3876910D1 (de) Kugelfoermiger zyklon.
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
DE68923795D1 (de) Herstellung von alkylbenzolen.
DE68921340D1 (de) Herstellung von epoxinitraten.
DE3875281D1 (de) Herstellung von pseudoiononen.
DE3851903D1 (de) Herstellung von Tabletten.
PT87765A (pt) Kontinuierlich variables laserstrahl-daempfungsglied
DE3860318D1 (de) Gewebe-schlitzgeraet.
DE3884481D1 (de) Oszillierender kreisel.
NO871131L (no) Viskometer.
DE3881393D1 (de) Dehydrobromierung von substituiertem alpha-halocumol.
KR890008317U (ko) 머리핀
ATE43849T1 (de) Orientierung von kollagen.
ATE99667T1 (de) Herstellung von hexanitrostilben.
DE68916334D1 (de) Herstellungsverfahren von beta-Acyloxypropionaldehyd.
SE8701928D0 (sv) Tyst flekt
ATE90974T1 (de) Gewinnung von magnesium.
ES1009381Y (es) Juego de agua-boligrafo.
SE8701758D0 (sv) Stridsdel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee